Millendo Therapeutics (NASDAQ:MLND) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Millendo Therapeutics (NASDAQ:MLND) released its quarterly earnings data on Monday. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.07, Bloomberg Earnings reports.

Millendo Therapeutics stock opened at $6.97 on Thursday. The business has a 50 day moving average price of $10.36. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. The firm has a market cap of $100.39 million, a price-to-earnings ratio of -0.40 and a beta of 2.64.

Several research firms recently weighed in on MLND. ValuEngine upgraded shares of Millendo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Oppenheimer dropped their price target on shares of Millendo Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday. Citigroup began coverage on shares of Millendo Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research upgraded shares of Millendo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, CIBC began coverage on shares of Millendo Therapeutics in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 price target on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.25.



Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

See Also: Stochastic Momentum Index (SMI)

Earnings History for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.